GlassScriptPhysician profile
Blake Robbins
NPI 1184164923
$8,861.42
in general payments reported to CMS, 2019-2025
26 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $78.12 · 2021: $305 · 2022: $315 · 2023: $2,285 · 2024: $3,331 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,563 · Education: $98.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,562.87 |
| Education | $98.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,249.94 | 2021-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $760.45 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $704.12 | 2020-2025 | |
| Janssen Biotech, INC. | $687.02 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $645.33 | 2022-2025 | |
| Galderma Laboratories, L.P. | $454.39 | 2023-2025 | Aklief, Oracea, Nemluvio |
| Ucb, INC. | $419.38 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $361.99 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $344.79 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $331.30 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $328.84 | 2022-2025 | |
| Incyte Corporation | $305.09 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $250.99 | 2021-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $244.93 | 2023-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $194.03 | 2023-2024 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $154.97 | 2023-2024 | Adbry |
| Medimetriks Pharmaceuticals, INC. | $151.58 | 2023-2024 | Clindacin Etz, Tovet (Emollient Formulation) |
| Kerecis Limited | $125.27 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $97.72 | 2024-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $61.44 | 2022-2025 | |
| Organogenesis INC. | $55.85 | 2023-2024 | Puraply, Affinity |
| Almirall LLC | $55.57 | 2023-2024 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.03 | 2024-2025 | Spevigo |
| Organon LLC | $37.05 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $31.43 | 2025 | Xtrac |
| Journey Medical Corporation | $12.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.